Application of melatonin in preparation of medicine for treating neonatal hypoxic ischemic encephalopathy

By using a combination of melatonin and probiotics, the problem of poor treatment of hypoxic ischemic encephalopathy in neonatals is solved, significantly protecting nerve cells and improving neural function, providing better therapeutic effects.

CN118986971APending Publication Date: 2024-11-22QINGDAO WOMEN & CHILDREN HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411459614.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-18
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art has limited effect in treating neonatal hypoxic ischemic encephalopathy and is difficult to effectively improve long-term prognosis.

Method used

Melatonin is used as the main ingredient, combined with probiotics such as Bifidobacterium, Streptococcus faecalis, and Lactobacillus, and administered or gavage-induced medications. It is used to treat neonatal hypoxic ischemic encephalopathy and enhance the protection of nerve cells.

Benefits of technology

Melatonin significantly protects nerve cells, blocks HI-induced mitochondrial autophagy, and combines the use of probiotics to further improve the therapeutic effect and improve neurological and structural damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986971A_ABST
    Figure CN118986971A_ABST
Patent Text Reader

Abstract

The invention discloses application of melatonin in preparation of medicine for treating neonatal hypoxic-ischemic encephalopathy, and relates to the technical field of hypoxic-ischemic encephalopathy. Experimental results show that when the melatonin with the dosage of 5-40 mg / kg is used in a safe dosage range, the functional abundance of a neonatal rat hypoxic-ischemic model can be remarkably improved, and the function abundance of the neonatal hypoxic-ischemic encephalopathy can be remarkably improved. The traditional Chinese medicine composition is used for treating long-term neurological function damage of newborn rats caused by hypoxia ischemia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of hypoxic-ischemic encephalopathy, and in particular to use of melatonin in preparing a medicament for treating hypoxic-ischemic encephalopathy in newborns. Background Art

[0002] Hypoxic-ischemic encephalopathy (HIE) is a neurological injury caused by lack of oxygen or reduced blood flow to the brain. HIE is common in newborns and infants. When perinatal asphyxia, placental insufficiency, umbilical cord blood flow obstruction and other conditions occur, HIE not only leads to severe neurological dysfunction, but may also cause long-term sequelae such as mental retardation, movement disorders and epilepsy. Traditional treatments include lowering brain temperature (hypothermia therapy), anticonvulsant drugs and supportive care, but these methods have limited effects in improving long-term prognosis.

[0003] In recent years, studies have shown that melatonin has significant potential in neuroprotection. Melatonin is an endogenous hormone secreted by the pineal gland that has antioxidant, anti-inflammatory and immune system regulatory effects. Its unique physiological functions make it a potential neuroprotectant. Melatonin can protect nerve cells by scavenging free radicals, inhibiting oxidative stress, reducing inflammatory responses and regulating apoptosis signaling pathways.

[0004] Therefore, proposing a new method for treating HIE with melatonin as the main ingredient not only has important theoretical significance, but also has broad prospects for clinical application. Summary of the invention

[0005] The purpose of the present invention is to solve the problem that hypoxic-ischemic encephalopathy is difficult to treat in the prior art and to study the use of melatonin in treating neonatal hypoxic-ischemic encephalopathy.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions: Use of melatonin in the preparation of a drug for treating neonatal hypoxic-ischemic encephalopathy, wherein the melatonin structural formula is shown in formula (1): Formula (1).

[0007] Preferably, the single dose of melatonin is 5-40 mg / kg.

[0008] Preferably, the single dose of melatonin is 20-40 mg / kg.

[0009] Preferably, the melatonin is used in combination with probiotics, and the probiotics are one or more of Bifidobacterium, Streptococcus faecalis, and Lactobacillus acidophilus.

[0010] Preferably, the single dosage of the probiotics is 10-40 mg / kg.

[0011] Preferably, it is characterized in that the melatonin administration method is one of oral administration and intragastric administration.

[0012] Preferably, the melatonin is dissolved in anhydrous ethanol and then diluted with physiological saline for use.

[0013] The present invention has found through research that melatonin shows good therapeutic effects in the treatment of hypoxic-ischemic encephalopathy. Animal model studies have shown that melatonin plays a protective role on brain cells that have undergone hypoxic-ischemic damage, and as the dosage of melatonin increases, it can better protect the mitochondria of nerve cells and block HI-induced mitochondrial autophagy of nerve cells.

[0014] At the same time, the present invention further adopts probiotics combined with melatonin for treatment, and the probiotics used in combination include bifidobacterium, streptococcus faecalis and lactobacillus acidophilus, and has better application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The expression diagram of mitochondria-related autophagy proteins in the MelA group, MelB group, HI group and Sham group in the embodiment of the present invention; Figure 2 This is a comparison chart of PINK1 expression data of mitochondrial autophagosomes after medication in the MelB group, MelProA group, HI group and Sham group in the embodiment of the present invention; Figure 3 This is a comparison chart of PINK1 expression data of mitochondrial autophagosomes after medication in the MelB group, MelProA group, HI group and Sham group in the embodiment of the present invention; Figure 4 Electron microscopic images of mitochondrial autophagosomes in the MelB group, MelProA group, HI group and Sham group after drug administration in the embodiment of the present invention; Figure 5 This is an electron microscopic image of the mitochondrial autophagosome lesions in the HI group in the embodiment of the present invention; Figure 6 This is a diagram showing the abundance differences among HI group, MelB group, MelProA group, Pro group and Sham group after medication in the embodiment of the present invention; Figure 7 Boxplot diagram of top 10 differences in abundance among different groups in all embodiments of the present invention; Figure 8 It is a functional box plot of significant differences between different groups in all embodiments of the present invention; Fig. 9 The top 30 information hotspots with significant differences in functional abundance among different groups in all embodiments of the present invention Figure 1 ; Fig.10 The distribution of LDA values ​​of significant differences between the same groups in all embodiments of the present invention Figure 1 ; Fig.11 The distribution of LDA values ​​of significant differences between the same groups in all embodiments of the present invention Figure 2 ; Fig.12 The distribution of LDA values ​​of significant differences between the same groups in all embodiments of the present invention Figure 3 ; Fig.13 The distribution of LDA values ​​of significant differences between the same groups in all embodiments of the present invention Figure 4 ; Fig.14 The distribution of LDA values ​​of significant differences between the same groups in all embodiments of the present invention Figure 5 ; Fig.15 Electron microscopic images of mitochondrial autophagosomes in the MelB group, MelProA group, HI group and Sham group after drug administration in the embodiment of the present invention; Fig.16 This is a schematic diagram of the expression of the myelin protein marker MBP and the neuron synapse marker Syn-1 in the embodiment of the present invention; Fig.17 This is a comparison chart of the expression data of mitochondrial autophagosome MBP in the MelB group, MelProA group, HI group and Sham group in the embodiment of the present invention; Fig.18 This is a comparison chart of the expression data of mitochondrial autophagosome Syn-1 in the MelB group, MelProA group, HI group and Sham group in the embodiment of the present invention; Fig.19 The typical graphs of field potential recordings of the MelB group, MelProA group, HI group and Sham group in the embodiment of the present invention; Fig. 20 Graph showing the relationship between field potential input and output of brain slices in MelB group, MelProA group, HI group and Sham group in the embodiment of the present invention; Fig.21 Schematic diagram of the water maze behavioral experiment principle in all embodiments of the present invention; Fig. 22 It is the escape latency diagram of MelB group, MelProA group, HI group and Sham group in the embodiment of the present invention; Fig.23 3 is a graph showing the proportion of exercise time in the target quadrant of rats in the MelB group, MelProA group, HI group and Sham group in the embodiment of the present invention. DETAILED DESCRIPTION

[0016] The following will be combined with the accompanying drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. The melatonin used in the following embodiments is the structure shown in formula (1).

[0017] Formula (1): .

[0018] 1. Handling of Experimental Animals Three-day-old SD rats were anesthetized by inhalation of 2% isoflurane, fixed on the operating table in a supine position, and the left common carotid artery was exposed under a dissecting microscope. A 0.5-1.0 cm longitudinal incision was made on the left side of the neck close to the trachea, and the left common carotid artery was ligated with a 7 / 0 disposable suture. The artery was cut between the two ends of the ligature, and the incision was sutured. After the operation, the rats were returned to the mother to recover for 1 hour after waking up, and placed in a mixed gas (8% O2+92% ​​N2) continuous input box for 2.5 hours, with a gas flow of 2 L / min and an oxygen concentration of 8%.

[0019] 2. Preparation of experimental drugs (1) Dissolve one Bifidobacterium capsule in 1 ml of water for injection. One capsule is approximately 230 mg. (2) Dissolve 10 mg of melatonin in 0.5 ml of anhydrous ethanol and dilute to 10 ml with 0.9% saline.

[0020] Example 1 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten sick newborn rats are randomly divided into a group, wherein a single dose of melatonin is 5 mg / kg for newborn rats, and the drug is continuously administered for 1-5 consecutive days. This rat group is recorded as MelA group.

[0021] Example 2 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten sick newborn rats were randomly divided into a group, in which the single application dose of melatonin was 20 mg / kg for newborn rats, and the drug was continuously administered for 1-5 consecutive days. This rat group was recorded as MelB group.

[0022] Example 3 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten sick newborn rats were randomly divided into a group, in which the single application dose of melatonin was 40 mg / kg for newborn rats, and the drug was continuously administered for 1-5 consecutive days. This rat group was recorded as MelC group.

[0023] Example 4 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten sick newborn rats were randomly divided into a group, in which the single application dose of melatonin was 20 mg / kg for newborn rats, and the combined medication was bifidobacterium, and the single application dose of bifidobacterium was 10 mg / kg for newborn rats. The drugs were continuously administered for 1-5 days. This rat group was recorded as MelProA group.

[0024] Example 5 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten sick newborn rats were randomly divided into a group, in which the single application dose of melatonin was 20 mg / kg for newborn rats, and the combined medication was fecal streptococcus, and the single application dose of fecal streptococcus was 10 mg / kg for newborn rats. The medication was continued for 1-5 consecutive days. This rat group was recorded as MelProB group.

[0025] Example 6 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten sick newborn rats were randomly divided into a group, in which the single application dose of melatonin was 20 mg / kg for newborn rats, and the combined drug was Lactobacillus acidophilus, and the single application dose of Lactobacillus acidophilus was 10 mg / kg for newborn rats. The drugs were continuously administered for 1-5 days. This rat group was recorded as MelProC group.

[0026] Comparative Example 1 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten newborn rats without the disease were randomly divided into a group. The rats used were the sham operation group. The left common carotid artery of the rats in the sham operation group was separated, but not ligated, nor subjected to hypoxia treatment, and no therapeutic drugs were used. Normal saline was continuously injected for 1-5 consecutive days. This rat group was recorded as the Sham group.

[0027] Comparative Example 2 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten sick newborn rats were randomly divided into a group. The rats in this group were not treated with melatonin or probiotics. This rat group was recorded as the HI group.

[0028] Comparative Example 3 Melatonin is used as a pharmaceutical for the treatment of neonatal hypoxic-ischemic encephalopathy. Ten sick newborn rats were randomly re-selected and divided into a group. Bifidobacterium was used for treatment only. The single application dose of Bifidobacterium was 10 mg / kg for newborn rats. The drug was continuously administered for 1-5 consecutive days. This rat group was recorded as Pro group.

[0029] 3. Experimental Results (1) Effect of melatonin on alleviating mitochondrial damage in HI-induced hypoxic-ischemic encephalopathy Three rats were randomly selected from each of the MelA group, MelB group, HI group, and Sham group, and their brain tissues were sliced. The expression changes of mitochondrial autophagy protein Parkin / PINK1 were detected in each group of brain tissues, and the ultrastructural changes such as mitochondrial autophagy of brain cells were observed by electron microscopy. Figure 1-3 Compared with the Sham group, the expression of mitophagy-related marker protein PINK1 / Parkin in the HI group was generally increased, but the expression in the MelA group and MelB group was slightly reduced, and the reversal of mitophagy protein expression was more significant in MelB. This proves that, first of all, melatonin plays a protective role in brain cells after hypoxic-ischemic injury, and as the dosage of melatonin increases, it can better protect the mitochondria of nerve cells and block HI-induced mitophagy of nerve cells.

[0030] Further, refer to Figure 4 At least one rat was randomly selected from each of the MelB, MelProA, HI, and Sham groups, and its brain tissue sections were further observed under a transmission electron microscope. It was found that the Sham group remained relatively intact, while the mitochondrial structure of the HI group was significantly damaged, the cell membrane was significantly deformed and dissolved, and finally formed the following Figure 5 The mitochondrial autophagosomes shown in the figure are relatively complete in the MelB group only relative to the HI group, while in the MelProA group the mitochondrial structure is more complete, the cells are plump, and the nuclear chromatin is clearly visible. It can be concluded that compared with the treatment with melatonin alone, the use of bifidobacteria can increase the protective effect on brain cells after hypoxic-ischemic injury.

[0031] (2) Melatonin plus probiotics for the treatment of hypoxic-ischemic encephalopathy Reference Figure 6 and Figure 7 Compared with other groups, the group treated with melatonin and probiotics had the largest functional abundance. Figure 4 The MelProA group treated with probiotics combined with melatonin showed greater functional abundance than the other groups.

[0032] Further, refer to Figure 8 and Fig. 9The MelPro groups in the figure include MelProA group, MelProB group and MelProC group, and the Mel groups include MelA group, MelB group and MelC group. Red to blue in the figure represent the function abundance from large to small. In order to study whether there are significant differences in functions between different groups, the experiment starts from the function abundance table of different levels, and uses the Wilcoxon rank-sum method to perform hypothesis testing on the function abundance data between groups to obtain the p value. If p is less than 0.05, it is considered to be significantly different. It can be seen that most of the functional annotation information of the MelPro group treated with probiotics combined with melatonin is at the leading level.

[0033] Furthermore, in order to screen for functions with significant differences between groups, Figure 10-14 First, the differential functions between different groups were detected by the rank sum test method, and the linear discriminant analysis was used to achieve dimensionality reduction and evaluate the impact of the differential functions to obtain the LDA score. The LDA value distribution bar chart shows the functions with LDA score greater than the set value (the default setting is 2), that is, the Biomarkers with statistical differences between groups. The length of the bar chart represents the impact of the differential function.

[0034] Further, refer to Fig.15 On the basis of (1), the slices of rats selected from the MelB group, MelProA group, HI group and Sham group were magnified 25,000 times under a transmission electron microscope to observe the ultrastructure of the cells. It was found that the myelin lamellar structure of the HI group was loose, stratified, partially broken, and the organelles in the myelin sheath showed liquefaction necrosis. However, after treatment, the myelin structure of the MelProA group was neat and tight, and organelles with intact cell membranes were visible. Therefore, the addition of melatonin to bifidobacterium can better reduce the myelin damage caused by HI.

[0035] Further, refer to Figure 16-18 Western Blot was used to evaluate the improving effect of melatonin on myelination disorders caused by HI. It was found that the myelin protein marker MBP and neuronal synapse marker Syn-1 in the HI group were significantly reduced compared with other groups, affecting the myelination process of the nervous system. In the MelProA group, the expression of MBP and Syn-1 could be significantly upregulated, which could better promote the development of myelin and synapses.

[0036] Further, refer to Fig.19 and Fig. 20The induced compound action potentials in the right hemisphere of the corpus callosum (CC) and external capsule (EC) of rats in the MelB group, MelProA group, HI group and Sham group were detected. In the figure, A, B, C and D represent the Sham group, MelProA group, MelB group and HI group, respectively, and each group had 4 slices.

[0037] In the electrophysiological experiment of the central nervous system, it was found that compared with the Sham group, the HI group was able to stimulate the excitability of brain cells, and the frequency of peak potentials generated in the same period of time was significantly increased, while the MelProA group significantly reduced the excitability of nerve cells and also reduced the frequency of peak potentials in the same period of time (p<0.05).

[0038] Further, refer to Figure 21-23 Three rats were randomly selected from the MelB group, MelProA group, HI group and Sham group respectively, and water maze behavioral experiments were performed. The water maze experiment was used to evaluate the long-term neurological damage caused by HI after melatonin was added to bifidobacteria. According to the escape latency diagram of the first 4 days of the positioning cruise stage, it can be seen that the average escape latency of 28-day-old rats in the HI group was significantly higher than that in the Sham group (p<0.05), and the spatial exploration ability was also poor, and the proportion of movement time in the target quadrant was significantly reduced (p<0.05); this phenomenon was improved after the intervention of melatonin and bifidobacteria. The escape latency in the MelProA group was shorter than that in the HI group (p<0.05), and the movement time in the target quadrant increased (p<0.05).

[0039] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. Use of melatonin in the preparation of a drug for treating neonatal hypoxic-ischemic encephalopathy, characterized in that: The structural formula of melatonin is shown in formula (1): Formula (1).

2. The use of melatonin in the preparation of a drug for treating neonatal hypoxic-ischemic encephalopathy according to claim 1, characterized in that: The single dosage of melatonin is 5-40 mg / kg.

3. The use of melatonin in the preparation of a drug for treating neonatal hypoxic-ischemic encephalopathy according to claim 2, characterized in that: The single dosage of melatonin is 20-40 mg / kg.

4. The use of melatonin in the preparation of a drug for treating neonatal hypoxic-ischemic encephalopathy according to claim 1, characterized in that: The melatonin is used in combination with probiotics, and the probiotics are one or more of bifidobacterium, streptococcus faecalis, and lactobacillus.

5. The use of melatonin in the preparation of a drug for treating neonatal hypoxic-ischemic encephalopathy according to claim 4, characterized in that: The single dosage of the probiotics is 10-40 mg / kg.

6. Use of melatonin according to any one of claims 1 to 5 in the preparation of a drug for treating neonatal hypoxic-ischemic encephalopathy, characterized in that: The melatonin administration method is one of oral administration and intragastric administration.

7. Use of melatonin according to any one of claims 1 to 6 in the preparation of a drug for treating neonatal hypoxic-ischemic encephalopathy, characterized in that: The melatonin is dissolved in anhydrous ethanol and then diluted with physiological saline for use.